How Is Regeneron Pharmaceuticals' Stock Performance Compared to Other Biotechnology Stocks?

Regeneron Pharmaceuticals, Inc. (REGN), with a market cap of $110.4 billion, is a leading biotechnology company based in Tarrytown, New York. Specializing in the discovery, development, and commercialization of treatments for various diseases, Regeneron focuses on diverse therapeutic areas such as ophthalmology, immunology, and infectious diseases.

Companies valued at $10 billion or more are generally considered “large-cap” stocks, and Regeneron Pharmaceuticals fits this criterion perfectly, exceeding the mark. Regeneron Pharmaceuticals stands out for its robust portfolio of innovative drugs targeting various serious medical conditions, including groundbreaking treatments like Eylea, Dupixent, and REGEN-COV2, the latter being a significant milestone in the fight against COVID-19.

Despite Regeneron down just 1.4% from its 52-week high of $1,016, achieved on June 6, its shares are up 3.4% over the past three months, outperforming the broader Nasdaq Biotechnology Ishares ETF's (IBB) 1.2% dip over the same time frame. 

www.barchart.com

Longer term, REGN is up 14.1% on a YTD basis, outpacing IBB's marginal gains. Moreover, shares of Regeneron Pharmaceuticals have gained 34.2% over the past 52 weeks, compared to IBB's 6.3% gains over the same time frame.

To validate its bullish trend, REGN has consistently traded above its 200-day moving average since August last year and remained mostly above its 50-day moving average with a few fluctuations. 

www.barchart.com

REGN has been outperforming due to positive developments in its patent suits protecting its key drug, Eylea, successful Food and Drug Administration (FDA) approval of its high-dose Eylea formulation, and robust revenue growth from flagship products like Dupixent. Moreover, the stock surged 3.8% on May 2 after its Q1 earnings results, buoyed by robust sales of a high-dose version of its blockbuster eye disease treatment, Eylea, which overshadowed profit misses. 

To emphasize the stock’s outperformance, Regeneron’s top rival, Amgen Inc. (AMGN), gained 5.8% on a YTD basis, underperforming REGN over the same time frame. But shares of Amgen have gained 39.3% over the past 52 weeks, outpacing REGN’s gains over the same period.

The analysts are optimistic about REGN stock's prospects. The stock has a consensus rating of “Strong Buy” from the 26 analysts covering the stock, and the mean price target of $1,043 represents a premium of just 4.1% to current levels. 

More Stock Market News from Barchart

• Medtronic Stock: Is MDT Underperforming the Healthcare Sector?
• Is The Boeing Stock Underperforming the Dow?
• Is Chubb Limited Stock Outperforming the Nasdaq?
• Is Boston Scientific Stock Outperforming the S&P 500?

On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.